Subcutaneous efgartigimod has been FDA- approved in the USA for treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), and that two more Fc receptor (FcRn) antagonists, rozanolixizumab and nipocalimab are also approved for generalized AchR and MuSK antibody positive myasthenia gravis (4). The gene discussed is MUSK; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.